Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 2.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,106 shares of the medical research company's stock after selling 1,243 shares during the quarter. CIBC Private Wealth Group LLC owned 0.15% of Bio-Rad Laboratories worth $14,500,000 as of its most recent filing with the Securities and Exchange Commission.

• S&P 500 Shake-Up: New Entrants Driving Market Momentum

Other large investors have also recently made changes to their positions in the company. Venturi Wealth Management LLC grew its position in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after buying an additional 87 shares during the last quarter. Picton Mahoney Asset Management boosted its stake in shares of Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after acquiring an additional 35 shares in the last quarter. Asset Planning Inc acquired a new stake in Bio-Rad Laboratories in the 4th quarter valued at about $33,000. UMB Bank n.a. grew its holdings in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after buying an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. purchased a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth about $38,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Royal Bank of Canada restated an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Wells Fargo & Company dropped their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. Finally, StockNews.com cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $395.20.

• The Top 3 Medical Devices Stocks to Buy Now

Read Our Latest Research Report on BIO

Bio-Rad Laboratories Stock Up 0.5 %

Shares of NYSE BIO opened at $244.29 on Tuesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. Bio-Rad Laboratories, Inc. has a 1 year low of $235.84 and a 1 year high of $387.99. The stock's 50-day simple moving average is $291.56 and its 200-day simple moving average is $321.95. The firm has a market cap of $6.84 billion, a price-to-earnings ratio of -3.76 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Featured Stories

• Five stocks we like better than Bio-Rad Laboratories
• Should You Add These Warren Buffett Stocks to Your Portfolio?
• 3 Buyable Stocks With Solid Bottoms Ready to Rebound
• 3 Stocks to Consider Buying in October
• Advantage+ Shopping: Meta's Fast Growing $20 Billion AI-Ads Star
• About the Markup Calculator
• Robotaxi News: What Tesla and Lyft Headlines Mean for Shares

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bio-Rad Laboratories Right Now?

Before you consider Bio-Rad Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.

While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here